Objective：To observe the expressions of human trophoblast cell surface antigen 2（TROP2）and vascular endothelial growth factor receptor 2（VEGFR2）in triple negative breast cancer（TNBC），and explore their correlation with clinicopathological factors and prognosis. Methods：The expressions of TROP2 and VEGFR2 in 151 cases of TNBC，137 cases of non-TNBC，48 cases of benign breast tumor and 48 cases of normal breast tissues were detected by immunohistochemical method（two-step method）. Results：TROP2 and VEGFR2 were expressed in the cell membrane and cytoplasm of breast cancer cells，respectively. The TROP2 and VEGFR2 protein was highly expressed in TNBC，and their positive rates were higher than those in non-TNBC，benign breast tumor and normal breast tissues. The co-expression of TROP2 and VEGFR2 in TNBC was higher than that in non- TNBC，and the difference was statistically significant. The positive expressions of TROP2 and VEGFR2 in TNBC tissues and the high co-expression of TROP2 and VEGFR2 in TNBC were associated with the histological grade，clinical stage and metastasis of patients. The high co-expression of TROP2 and VEGFR2 proteins is an independent prognostic index of TNBC. Conclusion：TROP2 and VEGFR2 can be used as a new molecular target for TNBC，which can be expected to facilitate the prognosis evaluation and immune-targeting treatment of TNBC.